サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1587794

リンパ腫治療の市場規模、シェア、動向分析レポート：タイプ別、薬剤別、地域別、セグメント別予測、2025年～2030年

Lymphoma Treatment Market Size, Share & Trends Analysis Report By Type (Hodgkin Lymphoma, Non-Hodgkin Lymphoma), By Drugs (Adcetris, Opdivo, Rituxan, Imbruvica, Keytruda), By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
リンパ腫治療の市場規模、シェア、動向分析レポート：タイプ別、薬剤別、地域別、セグメント別予測、2025年～2030年
出版日: 2024年10月08日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

リンパ腫治療市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のリンパ腫治療市場規模は2025年から2030年にかけてCAGR 8.3％を記録し、2030年には119億7,000万米ドルに達すると予測されています。

新たな治療法開発のための研究活動の活発化と製品ラインナップの拡大が成長を促進する可能性が高いです。新薬の商業化の増加がさらに成長を促進すると予想されます。

多種多様な製品の入手可能性は、さらに成長を助長すると予想されます。例えば、2019年1月、ベイジーンは、成人のマントル細胞リンパ腫を治療する製品Zanubrutinibについて米国FDAから画期的治療薬指定を受けた。この薬剤は現在後期臨床試験中であり、予測期間中に上市される見込みです。

医療従事者や患者の間でリンパ腫の早期診断に対する認識が高まっていることや、研究開発に対する政府の資金援助が増加していることは、市場の成長を促進すると予想されるいくつかの要因です。例えば、米国国立がん研究所（National Cancer Institute）などの研究機関は、米国議会からがん関連の研究や関連活動を支援するための資金援助を受けています。

リンパ腫治療市場レポート・ハイライト

  • 非ホジキンリンパ腫（NHL）が2024年に86.2%の最大売上シェアで市場を独占し、NHLの罹患率の増加が牽引し、今後数年間で症例数が大幅に増加すると予測されています。
  • ホジキンリンパ腫（HL）は、診断症例数の増加と早期発見を促進する診断技術の進歩により、予測期間中にCAGR 15.7％で成長する見込みです。
  • リツキサン（マブセラ）が市場を独占し、2024年には28.8%の最大売上シェアを占めました。これは、その確立された有効性と、非ホジキンリンパ腫（NHL）を中心とするさまざまな適応症での幅広い使用によるものです。
  • キイトルーダは、特に進行または難治性の症例に対する主要な免疫療法の選択肢であることから、予測期間中に18.9%のCAGRで最速の成長が見込まれます。
  • 病院薬局が市場を独占し、2024年には36.1％の最大の売上シェアを占めました。
  • 北米のリンパ腫治療市場は世界市場を席巻し、2024年には49.0％の最大売上シェアを占めたが、これはリンパ腫症例、特に非ホジキンリンパ腫の有病率の高さに起因します。
  • アジア太平洋地域のリンパ腫治療市場は、罹患率の上昇とヘルスケア支出の増加により急速に成長すると予測されます。この地域の国々は、ヘルスケアインフラの改善と革新的治療へのアクセスを経験しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 リンパ腫治療市場の変数、動向、範囲

  • 市場系統の見通し
  • 市場力学
    • 市場 促進要因分析
    • 市場抑制要因分析
  • ビジネス環境分析
    • 業界分析- ポーターのファイブフォース分析
    • PESTLE分析

第4章 リンパ腫治療市場：薬剤推定・動向分析

  • セグメントダッシュボード
  • リンパ腫治療市場：薬剤変動分析、2024年および2030年
  • ホジキンリンパ腫
  • 非ホジキンリンパ腫

第5章 リンパ腫治療市場：薬剤推定・動向分析

  • セグメントダッシュボード
  • リンパ腫治療市場：薬剤変動分析、2024年および2030年
  • リツキサン/マブセラ
  • レブラミド
  • イブルビカ
  • アドセトリス
  • キイトルーダ
  • オプジーボ
  • その他

第6章 リンパ腫治療市場：流通チャネル推定・動向分析

  • セグメントダッシュボード
  • リンパ腫治療市場：流通チャネル変動分析、2024年および2030年
  • 病院薬局
  • 小売薬局
  • 専門薬局
  • その他

第7章 リンパ腫治療市場：地域推定・動向分析

  • 地域別市場シェア分析、2024年および2030年
  • 地域市場ダッシュボード
  • 市場規模、予測動向分析、2018年から2030年：
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • アラブ首長国連邦

第8章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業分類
  • 企業ヒートマップ分析
  • 企業プロファイル
    • Bristol-Myers Squibb Company
    • Celgene Corporation
    • Merck &Co., Inc.
    • F. Hoffmann-La Roche Ltd
    • Seattle Genetics, Inc.
    • Takeda Pharmaceutical Company Ltd
    • Johnson &Johnson
    • Eli Lilly and Company
    • AstraZeneca
    • Novartis AG
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Lymphoma Treatment Market, by Region, 2018 - 2030 (USD Million)
  • Table 4 Global Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 5 Global Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 6 Global Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 7 North America Lymphoma Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 8 North America Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 9 North America Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 10 North America Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 U.S Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 12 U.S Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 13 U.S Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 14 Canada Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 15 Canada Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 16 Canada Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 17 Mexico Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 18 Mexico Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 19 Mexico Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 20 Europe Lymphoma Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 21 Europe Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 22 Europe Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 23 Europe Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 24 UK Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 25 UK Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 26 UK Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 27 Germany Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 28 Germany Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 29 Germany Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 30 France Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 31 France Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 32 France Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 33 Italy Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 34 Italy Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 35 Italy Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 36 Spain Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 37 Spain Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 38 Spain Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 39 Asia Pacific Lymphoma Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 43 Japan Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 44 Japan Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 45 Japan Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 46 China Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 47 China Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 48 China Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 49 India Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 50 India Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 51 India Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 52 Australia Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 53 Australia Lymphoma Treatment Market, by portability, 2018 - 2030 (USD Million)
  • Table 54 Australia Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 55 Australia Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 56 South Korea Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 57 South Korea Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 58 South Korea Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 59 Latin America Lymphoma Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 60 Latin America Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 61 Latin America Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 62 Latin America Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 63 Brazil Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 64 Brazil Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 65 Brazil Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 66 Argentina Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 67 Argentina Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 68 Argentina Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 69 Middle East & Africa Lymphoma Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 70 Middle East & Africa Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 71 Middle East & Africa Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 72 Middle East & Africa Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 73 South Africa Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 74 South Africa Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 75 South Africa Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 76 UAE Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 77 UAE Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 78 UAE Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Lymphoma treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Product and type outlook (USD Million)
  • Fig. 10 Type, drug, and distribution channel outlook
  • Fig. 11 Competitive landscape
  • Fig. 12 Lymphoma treatment market dynamics
  • Fig. 13 Lymphoma treatment market: Porter's five forces analysis
  • Fig. 14 Lymphoma treatment market: PESTLE analysis
  • Fig. 15 Lymphoma treatment market: Type segment dashboard
  • Fig. 16 Lymphoma treatment market: Type market share analysis, 2024 & 2030
  • Fig. 17 Hodgkin lymphoma market, 2018 - 2030 (USD Million)
  • Fig. 18 Non-Hodgkin lymphoma market, 2018 - 2030 (USD Million)
  • Fig. 19 Lymphoma treatment market: Drug segment dashboard
  • Fig. 20 Lymphoma treatment market: Drug market share analysis, 2024 & 2030
  • Fig. 21 Adcetris market, 2018 - 2030 (USD Million)
  • Fig. 22 Opdivo market, 2018 - 2030 (USD Million)
  • Fig. 23 Rituxan/MabThera market, 2018 - 2030 (USD Million)
  • Fig. 24 Imbruvica market, 2018 - 2030 (USD Million)
  • Fig. 25 Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 26 Revlimid market, 2018 - 2030 (USD Million)
  • Fig. 27 Others market, 2018 - 2030 (USD Million)
  • Fig. 28 Lymphoma treatment market: Distribution Channel segment dashboard
  • Fig. 29 Lymphoma treatment market: Distribution Channel market share analysis, 2024 & 2030
  • Fig. 30 Hospital pharmacy market, 2018 - 2030 (USD Million)
  • Fig. 31 Retail pharmacy market, 2018 - 2030 (USD Million)
  • Fig. 32 Specialty pharmacy market, 2018 - 2030 (USD Million)
  • Fig. 33 Lymphoma treatment market revenue, by region
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 Regional marketplace: Key takeaways
  • Fig. 36 North America lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 37 U.S. country dynamics
  • Fig. 38 U.S. lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 39 Canada country dynamics
  • Fig. 40 Canada lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 41 Mexico country dynamics
  • Fig. 42 Mexico lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 43 Europe lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 44 UK country dynamics
  • Fig. 45 UK lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 46 Germany country dynamics
  • Fig. 47 Germany lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 48 France country dynamics
  • Fig. 49 France lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 50 Italy country dynamics
  • Fig. 51 Italy lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 52 Spain country dynamics
  • Fig. 53 Spain lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 54 Norway country dynamics
  • Fig. 55 Norway lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 56 Sweden country dynamics
  • Fig. 57 Sweden lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 58 Denmark country dynamics
  • Fig. 59 Denmark lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 60 Asia Pacific lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 61 Japan country dynamics
  • Fig. 62 Japan lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 63 China country dynamics
  • Fig. 64 China lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 65 India country dynamics
  • Fig. 66 India lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 67 Australia country dynamics
  • Fig. 68 Australia lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 69 South Korea country dynamics
  • Fig. 70 South Korea lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 71 Thailand country dynamics
  • Fig. 72 Thailand lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 73 Latin America lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 74 Brazil country dynamics
  • Fig. 75 Brazil lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 76 Argentina country dynamics
  • Fig. 77 Argentina lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 78 MEA lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 79 South Africa country dynamics
  • Fig. 80 South Africa lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 81 Saudi Arabia country dynamics
  • Fig. 82 Saudi Arabia lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 83 UAE country dynamics
  • Fig. 84 UAE lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 85 Kuwait Key country dynamics
  • Fig. 86 Kuwait lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 87 Company categorization
  • Fig. 88 Company market position analysis
  • Fig. 89 Strategic framework
目次
Product Code: GVR-3-68038-983-8

Lymphoma Treatment Market Growth & Trends:

The global lymphoma treatment market size is expected to reach USD 11.97 billion by 2030, registering a CAGR of 8.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rising research activities for development of new treatments and increasing product line extension are likely to expedite growth. Increasing commercialization of novel drugs are further expected to drive the growth.

Availability of wide variety of products is further expected to aid growth. For instance, in January 2019, BeiGene received a breakthrough therapy designation by the U.S. FDA for its product Zanubrutinib for treating mantle cell lymphoma in adults. This drug is currently in late-stage clinical trial and is expected to be launched during the forecast period.

Growing awareness about early diagnosis of lymphoma among healthcare professionals & patients and rising government funding for R&D are some factors expected to propel market growth. For instance, institutes such as National Cancer Institute receives funding from the U.S. Congress to support cancer-related research and associated activities.

Lymphoma Treatment Market Report Highlights:

  • Non-Hodgkin Lymphoma (NHL) dominated the market with the largest revenue share of 86.2% in 2024, driven by the increasing incidence of NHL, with projections indicating a significant rise in cases over the coming years.
  • Hodgkin Lymphoma (HL) is expected to grow at a CAGR of 15.7% over the forecast period attributed to a rising number of diagnosed cases and advancements in diagnostic technologies that facilitate earlier detection.
  • Rituxan (MabThera) dominated the market and accounted for the largest revenue share of 28.8% in 2024, attributed to its established efficacy and broad usage across various indications, particularly non-Hodgkin lymphoma (NHL).
  • Keytruda is expected to grow at the fastest CAGR of 18.9% over the forecast period, owing to its status as a leading immunotherapy option, particularly for advanced or refractory cases.
  • Hospital pharmacies dominated the market and accounted for the largest revenue share of 36.1% in 2024 attributed to the increasing prevalence of lymphoma cases requiring specialized care.
  • The lymphoma treatment market in North America dominated the global market and accounted for the largest revenue share of 49.0% in 2024, owing to the high prevalence of lymphoma cases, particularly non-Hodgkin lymphoma, which accounts for a significant portion of cancer diagnoses.
  • The Asia Pacific lymphoma treatment market is projected to grow rapidly due to rising incidence rates and increasing healthcare spending. Countries in this region are experiencing improvements in healthcare infrastructure and access to innovative treatments

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Drug
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Lymphoma Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrant
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Lymphoma Treatment Market: Drug Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Lymphoma Treatment Market: Drug Movement Analysis, 2024 & 2030 (USD Million)
  • 4.3. Hodgkin Lymphoma
    • 4.3.1. Hodgkin Lymphoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Non-Hodgkin Lymphoma
    • 4.4.1. Non-Hodgkin Lymphoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Lymphoma Treatment Market: Drug Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Lymphoma Treatment Market: Drug Movement Analysis, 2024 & 2030 (USD Million)
  • 5.3. Rituxan/MabThera
    • 5.3.1. Rituxan/MabThera Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Revlimid
    • 5.4.1. Revlimid Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Imbruvica
    • 5.5.1. Imbruvica Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Adcetris
    • 5.6.1. Adcetris Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Keytruda
    • 5.7.1. Keytruda Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Opdivo
    • 5.8.1. Opdivo Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Lymphoma Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Lymphoma Treatment Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
  • 6.3. Hospital Pharmacy
    • 6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacy
    • 6.4.1. Retail Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Specialty Pharmacy
    • 6.5.1. Specialty Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Lymphoma Treatment Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. UAE
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. UAE Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Bristol-Myers Squibb Company
      • 8.4.1.1. Overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Celgene Corporation
      • 8.4.2.1. Overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Merck & Co., Inc.
      • 8.4.3.1. Overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. F. Hoffmann-La Roche Ltd
      • 8.4.4.1. Overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Seattle Genetics, Inc.
      • 8.4.5.1. Overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Takeda Pharmaceutical Company Ltd
      • 8.4.6.1. Overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Johnson & Johnson
      • 8.4.7.1. Overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Eli Lilly and Company
      • 8.4.8.1. Overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. AstraZeneca
      • 8.4.9.1. Overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Novartis AG
      • 8.4.10.1. Overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives